KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Income from Continuing Operations: 2009-2024

Historic Income from Continuing Operations for Neogenomics (NEO) over the last 16 years, with Dec 2024 value amounting to -$78.7 million.

  • Neogenomics' Income from Continuing Operations fell 53.28% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.5 million, marking a year-over-year decrease of 45.98%. This contributed to the annual value of -$78.7 million for FY2024, which is 10.51% up from last year.
  • Latest data reveals that Neogenomics reported Income from Continuing Operations of -$78.7 million as of FY2024, which was up 10.51% from -$88.0 million recorded in FY2023.
  • Neogenomics' 5-year Income from Continuing Operations high stood at $4.2 million for FY2020, and its period low was -$144.2 million during FY2022.
  • Its 3-year average for Income from Continuing Operations is -$103.6 million, with a median of -$88.0 million in 2023.
  • In the last 5 years, Neogenomics' Income from Continuing Operations crashed by 1,628.17% in 2022 and then soared by 39.02% in 2023.
  • Neogenomics' Income from Continuing Operations (Yearly) stood at $4.2 million in 2020, then slumped by 300.07% to -$8.3 million in 2021, then slumped by 1,628.17% to -$144.2 million in 2022, then spiked by 39.02% to -$88.0 million in 2023, then increased by 10.51% to -$78.7 million in 2024.